Allspring Global Investments Holdings LLC Buys 21,149 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Allspring Global Investments Holdings LLC boosted its stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 53.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,462 shares of the company’s stock after acquiring an additional 21,149 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.11% of Voyager Therapeutics worth $204,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Voyager Therapeutics by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 3,215,441 shares of the company’s stock worth $18,232,000 after purchasing an additional 29,014 shares during the last quarter. Farallon Capital Management LLC increased its stake in shares of Voyager Therapeutics by 12.2% during the 4th quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock worth $14,576,000 after purchasing an additional 278,700 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Voyager Therapeutics by 24.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock worth $7,828,000 after purchasing an additional 275,571 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Voyager Therapeutics by 151.0% during the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock worth $6,974,000 after purchasing an additional 740,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Voyager Therapeutics by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company’s stock worth $6,149,000 after purchasing an additional 4,729 shares during the last quarter. 48.03% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $13.39.

Voyager Therapeutics Stock Performance

NASDAQ VYGR opened at $3.49 on Friday. The firm’s 50 day moving average price is $3.20 and its 200-day moving average price is $3.96. Voyager Therapeutics, Inc. has a 52-week low of $2.65 and a 52-week high of $9.55. The company has a market cap of $193.14 million, a PE ratio of -2.39 and a beta of 0.85.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.18). The business had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million. Voyager Therapeutics had a negative return on equity of 27.36% and a negative net margin of 126.49%. On average, analysts forecast that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.